^
Association details:
| Biomarker: | ALK negative |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | etoposide IV (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
Published date:
01/29/2021
Excerpt:
The current report focuses on the characterization and evaluation of outcomes in 235 (15%) cases of ALK– ALCL....Treatment with anthracycline and etoposide was associated with a superior outcome: 3-year and 5-year OS rates were 56% and 44% in the anthracycline-based treatment group, and 76% and 69% in the anthracycline/etoposide–based treatment group, and the differences were statistically significant (P = .05). Similar results were also observed in PFS.
DOI:
10.1182/bloodadvances.2020001581
Trial ID:
